Who We Are and What We Do
At GlycoMimetics, we are committed to helping to make a difference in the lives of people living with sickle cell disease and various cancers. Our mission is to continue to advance our research and clinical candidates, providing hope for patients as we strive for tomorrow’s breakthrough treatments.
GlycoMimetics is a privately held clinical-stage biotechnology company. We use novel and proprietary glycobiology technology to develop treatments for diseases, especially those with high unmet needs. Since the company’s inception in 2003, we have developed a robust, diversified product pipeline.
The value of GlycoMimetics’ scientific approach and the potential of our product pipeline have been validated by investments from prestigious investors like New Enterprise Associates (NEA) and the venture funds of Novartis and Genzyme, as well as by our major partnership with Pfizer.